• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项关于临床试验中各种利益相关者所感知的实际参数及其相对重要性的研究。

A study of practical parameters and their relative importance as perceived by various stakeholders in clinical trials.

作者信息

Pant R, Joshi Y

机构信息

Himalayan Institute of Pharmacy & Research, Atak Farm, Rajawala, via Prem Nagar, Dehradun (Uttarakhand), India.

出版信息

J Young Pharm. 2011 Jan;3(1):60-4. doi: 10.4103/0975-1483.76421.

DOI:10.4103/0975-1483.76421
PMID:21607056
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3094562/
Abstract

A contract research organization (CRO) is a company which conducts a Good Clinical Practice (GCP) in clinical trial. There are literally hundreds of CROs worldwide employing a workforce of nearly 100,000 professionals. The project proposes the study of practical parameters and their relative importance as perceived by the various stakeholders in clinical trials. The survey was conducted in Bangalore and New Delhi. Primary market data was obtained by primary market research which included 80 clinical trial stakeholders by having a preliminary communication with them, followed by administering a questionnaire along with prior permission. There were 15 Sponsors/ CROs, 27 Investigators /Monitors and 38 Ethics committee members involved in the study. It was shown from the study that a clinical investigator involved in a clinical trial is responsible for ensuring that an investigation is conducted according to the signed investigator statement, the investigational plan, and applicable regulations; for protecting the rights, safety, and welfare of the subjects under the investigator's care; and for the control of drugs under investigation. It was also shown from the study that the sponsors of a clinical trial carry the ultimate responsibility for the initiation, management and financing of the clinical trial. The study has identified a specific training need at the level of the individual stakeholder to perform a particular job function and to identify the actual practical parameters in the Indian context important for the conduction of clinical trials (GCP) with respect to the different stakeholders, to determine the relative importance of these parameters as perceived by various stakeholders involved in clinical trials, and to identify the relative contributions of different stakeholders to the success/ satisfactory conduct of a clinical trial.

摘要

合同研究组织(CRO)是一家在临床试验中开展良好临床实践(GCP)的公司。全球实际上有数百个CRO,雇佣了近10万名专业人员。该项目提议研究临床试验中各利益相关者所感知的实际参数及其相对重要性。调查在班加罗尔和新德里进行。通过初步市场研究获得一手市场数据,包括与80名临床试验利益相关者进行初步沟通,然后在获得事先许可的情况下发放问卷。参与该研究的有15名申办者/CRO、27名研究者/监查员和38名伦理委员会成员。研究表明,参与临床试验的临床研究者有责任确保按照签署的研究者声明、研究计划和适用法规进行研究;保护研究者所负责受试者的权利、安全和福利;以及控制研究中的药物。研究还表明,临床试验的申办者对临床试验的启动、管理和资金承担最终责任。该研究确定了个体利益相关者层面的特定培训需求,以便履行特定工作职能,并确定在印度背景下对开展临床试验(GCP)而言重要的实际参数,这些参数对于不同利益相关者而言,确定各利益相关者所感知的这些参数的相对重要性,以及确定不同利益相关者对临床试验成功/令人满意开展的相对贡献。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c789/3094562/6fe6f24ed2ee/JYPharm-3-60-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c789/3094562/817d62474430/JYPharm-3-60-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c789/3094562/69856684f2f0/JYPharm-3-60-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c789/3094562/7e80ddecc55e/JYPharm-3-60-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c789/3094562/6fe6f24ed2ee/JYPharm-3-60-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c789/3094562/817d62474430/JYPharm-3-60-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c789/3094562/69856684f2f0/JYPharm-3-60-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c789/3094562/7e80ddecc55e/JYPharm-3-60-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c789/3094562/6fe6f24ed2ee/JYPharm-3-60-g004.jpg

相似文献

1
A study of practical parameters and their relative importance as perceived by various stakeholders in clinical trials.一项关于临床试验中各种利益相关者所感知的实际参数及其相对重要性的研究。
J Young Pharm. 2011 Jan;3(1):60-4. doi: 10.4103/0975-1483.76421.
2
American Society of Clinical Oncology policy statement: oversight of clinical research.美国临床肿瘤学会政策声明:临床研究监督
J Clin Oncol. 2003 Jun 15;21(12):2377-86. doi: 10.1200/JCO.2003.04.026. Epub 2003 Apr 29.
3
More than a box to check: Research sponsor and clinical investigator perspectives on making GCP training relevant.不止是打勾了事:研究资助方与临床研究者对使药物临床试验质量管理规范(GCP)培训具有相关性的看法。
Contemp Clin Trials Commun. 2020 Jul 2;19:100606. doi: 10.1016/j.conctc.2020.100606. eCollection 2020 Sep.
4
Culture of Care: Organizational Responsibilities关怀文化:组织职责
5
Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials.简化临床研究:提高临床试验赞助和监测的 ESMO 意识呼吁
Ann Oncol. 2023 Jan;34(1):70-77. doi: 10.1016/j.annonc.2022.09.162. Epub 2022 Oct 7.
6
Clinical trials integrity: a CRO perspective.临床试验的完整性:合同研究组织的视角
Account Res. 2001;8(3):245-60. doi: 10.1080/08989620108573977.
7
Improving the quality conduct and efficiency of clinical trials with training: Recommendations for preparedness and qualification of investigators and delegates.通过培训提高临床试验的质量、实施和效率:对研究者和代表的准备和资格的建议。
Contemp Clin Trials. 2020 Feb;89:105918. doi: 10.1016/j.cct.2019.105918. Epub 2019 Dec 24.
8
Evaluation of clinical trials by Ethics Committees in Germany--results and a comparison of two surveys performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa).德国伦理委员会对临床试验的评估——德国研发型制药企业协会(vfa)成员两项调查的结果及比较
Ger Med Sci. 2015 Jan 27;13:Doc02. doi: 10.3205/000206. eCollection 2015.
9
Stakeholders' recommendations for revising Good Clinical Practice.利益相关者对修订《药物临床试验质量管理规范》的建议。
Contemp Clin Trials Commun. 2021 Apr 16;22:100776. doi: 10.1016/j.conctc.2021.100776. eCollection 2021 Jun.
10
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.